Odey Friday, Okomo Uduak, Oyo-Ita Angela
Department of Paediatrics, University of Calabar Teaching Hospital, PMB 1115, Calabar, Cross River State, Nigeria, 540261.
Cochrane Database Syst Rev. 2018 Dec 5;12(12):CD006975. doi: 10.1002/14651858.CD006975.pub4.
Salmonella infections are a common bacterial cause of invasive disease in people with sickle cell disease especially children, and are associated with high morbidity and mortality rates. Although available in some centres, people with sickle cell anaemia are not routinely immunized with salmonella vaccines. This is an update of a previously published Cochrane Review.
To determine whether routine administration of salmonella vaccines to people with sickle cell disease reduces the morbidity and mortality associated with infection.
We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register which comprises of references identified from comprehensive electronic database searches and handsearches of relevant journals and abstract books of conference proceedings.We also conducted a search of the LILACS database and the World Health Organization International Clinical Trials Registry Platform (www.who.int/trialsearch) and ClinicalTrials.gov (www.clinicaltrials.gov).Date of most recent searches: 17 October 2018.
We planned to select all randomized controlled trials that compared the use of either the inactivated vaccine or an oral attenuated vaccine with a placebo among people with sickle cell disease. Equally, studies that compared the efficacy of one vaccine type over another were to be selected for the review.
No trials of salmonella vaccines in people with sickle cell disease were found.
There is an absence of randomized controlled trial evidence relating to the scope of this review.
AUTHORS' CONCLUSIONS: It is expected that salmonella vaccines may be useful in people with sickle cell disease, especially in resource-poor settings where the majority of those who suffer from the condition are found. Unfortunately, there are no randomized controlled trials on the efficacy and safety of the different types of salmonella vaccines in people with sickle cell disease. We conclude that there is a need for a well-designed, adequately-powered, randomized controlled trial to assess the benefits and risks of the different types of salmonella vaccines as a means of improving survival and decreasing mortality from salmonella infections in people with sickle cell disease. However, we believe that there are unlikely to be any trials published in this area, therefore, this review will no longer be regularly updated.
沙门氏菌感染是镰状细胞病患者（尤其是儿童）侵袭性疾病的常见细菌病因，且与高发病率和死亡率相关。尽管某些中心有沙门氏菌疫苗，但镰状细胞贫血患者通常未接种该疫苗。这是对先前发表的Cochrane系统评价的更新。
确定对镰状细胞病患者常规接种沙门氏菌疫苗是否能降低与感染相关的发病率和死亡率。
我们检索了Cochrane囊性纤维化和遗传疾病小组试验注册库，该注册库包含通过全面电子数据库检索以及对相关期刊和会议论文摘要集进行手工检索所确定的参考文献。我们还检索了LILACS数据库、世界卫生组织国际临床试验注册平台（www.who.int/trialsearch）和ClinicalTrials.gov（www.clinicaltrials.gov）。最新检索日期：2018年10月17日。
我们计划选择所有比较灭活疫苗或口服减毒疫苗与安慰剂在镰状细胞病患者中使用情况的随机对照试验。同样，比较一种疫苗类型与另一种疫苗类型疗效的研究也将被选入本评价。
未找到关于镰状细胞病患者接种沙门氏菌疫苗的试验。
本评价范围内缺乏随机对照试验证据。
预计沙门氏菌疫苗可能对镰状细胞病患者有用，尤其是在大多数此类患者所在的资源匮乏地区。遗憾的是，尚无关于不同类型沙门氏菌疫苗在镰状细胞病患者中的疗效和安全性的随机对照试验。我们得出结论，需要进行一项设计良好、样本量充足的随机对照试验，以评估不同类型沙门氏菌疫苗的益处和风险，作为提高镰状细胞病患者生存率和降低沙门氏菌感染死亡率的一种手段。然而，我们认为该领域不太可能再有试验发表，因此，本评价将不再定期更新。
